Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tolarex wins Israeli approval to initiate Phase I/IIa GVHD study
Tolarex, a Hadasit Bio Holdings portfolio company, has received approval from the Ministry of Health of Israel to begin a Phase I/IIa clinical trial of its treatment for
Tolarex, a Hadasit Bio Holdings portfolio company, has received approval from the Ministry of Health of Israel to begin a Phase I/IIa clinical trial of its treatment for
SpePharm, a Dutch specialty pharmaceutical company, has introduced two new products, MuGard and Xerotin, aimed at relieving some of the most debilitating side effects experienced by cancer patients,
The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client
Since its introduction in December 1993, Cravit has gained approval for treating 43 indications and 32 bacteria, the company said. Daiichi Sankyo drew on PK-PD theory to develop
Coldizin is scheduled for launch in the third quarter, in time for the ‘cough and cold season’, and Immulina is planned for launch in the fourth quarter. thin400
Alnylam Pharmaceuticals, an RNAi therapeutics company, has reported that the European Patent Office has issued a notification of intent to grant for a patent in the Tuschl I
With the CE-Marking, Biomerica said that its new one-step test can now be marketed directly to consumers through pharmacies in the EU. Biomerica’s home test, which will be
Biolex Therapeutics, a biopharmaceutical company, has started patient dosing in the Select-2 Phase IIb trial of its lead product candidate Locteron for the treatment of chronic hepatitis C.
Most recently an independent regulatory affairs consultant, Ms Rachel has also served as senior director and group head of regulatory affairs for the clinical research organization Averion International
CDA-1 and CDB-1 were co-developed by Medarex and Massachusetts Biologic Laboratories (MBL). Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize CDA-1 and